Drug Profile
Research programme: neurodegenerative disorder stem cell therapy - Cell Cure Neurosciences
Alternative Names: NeurArrestLatest Information Update: 06 Aug 2019
Price :
$50
*
At a glance
- Originator Cell Cure Neurosciences
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple sclerosis; Parkinson's disease
Most Recent Events
- 31 Jul 2019 BioTime is now called Lineage Cell Therapeutics
- 17 Jan 2018 BioTime has patent protection for Pluripotent cell technology in USA, Japan, Singapore, India and Europe
- 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in Israel (Parenteral)